Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation Felix Bahr, Rebekka Wehner, Uwe Platzbecker,

Slides:

Advertisements

Similar presentations

Allogeneic Hematopoietic Cell Transplantation in Patients Age Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous.

Advertisements

CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk.

Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.

Functional Myeloid-Derived Suppressor Cell Subsets Recover Rapidly after Allogeneic Hematopoietic Stem/Progenitor Cell Transplantation Qingdong Guan,

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.

Vaccination of Children following Allogeneic Stem Cell Transplantation

In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial Divya T. Koura, John T.

Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation.

High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.

Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation

Elevated Numbers of Immature/Transitional CD21− B Lymphocytes and Deficiency of Memory CD27+ B Cells Identify Patients with Active Chronic Graft-versus-Host.

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab Laura.

Individualized Dosing and Therapeutic Drug Monitoring (TDM) of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome Caroline Pical-Izard, Roberto.

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

CD161+ T Cells as Predictive Markers for Acute Graft-versus-Host Disease Sung-Eun Lee, Ji-Young Lim, Jae-Ho Yoon, Seung-Hwan Shin, Byung-Sik Cho, Ki-Seong.

Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cell–Supported Methods Steven A. Dezell,

Cytomegalovirus Immune Reconstitution Occurs in Recipients of Allogeneic Hematopoietic Cell Transplants Irrespective of Detectable Cytomegalovirus Infection

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD

Homeostatic γδ T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of γδ T Cell Subsets.

Expansion of NKG2A−LIR1− Natural Killer Cells in HLA-Matched, Killer Cell Immunoglobulin-Like Receptors/HLA-Ligand Mismatched Patients following Hematopoietic.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Thomas Yankee, Daisy Dai, Jignesh D

Betty T. Tran, Abigail Halperin, Jason W. Chien

Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network.

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute.

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.

Early Versus Late Allogeneic Hematopoietic Cell Transplantation in Patients with AML - Results From the Randomized AML 2003 Trial Gerhard Ehninger, Martin.

Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice Denis R. Burger, Yvonne Parker, Kathryn.

Biology of Blood and Marrow Transplantation

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal.

A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome Kitsada Wudhikarn, Claudio G. Brunstein, Veronika.

Relationship of CMV Reactivation and Rabbit Antithymocyte Globulin Administration in Allogeneic Stem Cell Transplant Patients LeAnne Kennedy, Marie Cavalier,

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients Pooja Khandelwal, Sabine Mellor-Heineke, Najibah.

Persistence of host dendritic cells after transplantation is associated with graft-versus- host disease Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller,

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation:

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell.

Mammen Chandy Biology of Blood and Marrow Transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation Felix Bahr, Rebekka Wehner, Uwe Platzbecker, Martin Wermke, Nona Shayegi, Jan Moritz Middeke, Christoph Röllig, Johannes Schetelig, Gerhard Ehninger, Marc Schmitz, Martin Bornhäuser, Sebastian Tuve Biology of Blood and Marrow Transplantation Volume 19, Issue 3, Pages 357-365 (March 2013) DOI: 10.1016/j.bbmt.2012.11.018 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Quantification of IFN-γ– and IL-17A–producing T helper cells using flow cytometry. Gating of IFN-γ−IL-17− (non-Th1/17), IFN-γ+IL-17− (Th1), IFN-γ+IL-17+ (TH1/17), and IFN-γ−IL-17+ (Th17) within the CD3+CD4+ T cell subset using intracellular cytokine staining. A representative flow chart of one patient 42 days after HCT is shown. (B and C) Reconstitution of lymphocytes (B) and CD3+CD4−/CD3+CD4+ T cells (C) after HCT. Data of patients with no complications (n = 29) are shown as dot plots (left panels) and columns (right panels). (Left panels) Dots represent cell counts (GPt/L or MPt/L) in one patient at one time point after HCT. Linear regression curves (trend lines) and R2 values are indicated. (Right panels) Columns show the mean cell counts (± SD) of healthy donors (n = 8) compared with patients (n = 29) at different time periods after HCT. *P < .05, **P < .01, ***P < .001, n.s., not significant. Biology of Blood and Marrow Transplantation 2013 19, 357-365DOI: (10.1016/j.bbmt.2012.11.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Reconstitution of IFN-γ– and IL-17–producing T helper cells after HCT. CD3+CD4+ T cells were quantified according to their production of IFN-γ and IL-17 (Figure 1A). Data of patients with no complications (n = 29) are shown as dot plots (left panels) and columns (right panels). (Left panels) Dots represent cell count (KPt/L) in one patient at one time point after HCT. Linear regression curves (trend lines) and R2 values are indicated. (Right panels) Columns show the mean cell counts (± SD) of healthy donors (n = 8) compared with patients (n = 29) at different time periods after HCT. *P < .05, **P < .01, ***P < .001, n.s., not significant. Biology of Blood and Marrow Transplantation 2013 19, 357-365DOI: (10.1016/j.bbmt.2012.11.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Effect of ATG on the reconstitution of lymphocytes (A), CD3+CD4−/CD3+CD4+ T cells (B), and Th1, Th17, and Th1/17 cells (C). Data of patients with ATG (n = 11) versus time-matched control subjects (n = 29) are shown. Mean quantity (± SD) of lymphocytes, CD3+CD4+/CD3+CD4− T cells, and T helper cells are indicated in GPt/L, MPt/L, or KPt/L at different time periods after HCT. *P < .05, **P < .01, ***P < .001, n.s., not significant. Biology of Blood and Marrow Transplantation 2013 19, 357-365DOI: (10.1016/j.bbmt.2012.11.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Impact of acute GVHD grade I (A-C) and II-IV (D-F) on the frequency of lymphocytes, CD3+CD4−/CD3+CD4+ T cells, and Th1, Th17, and Th1/17 cells. Data of patients with acute GVHD grade I (A-C, n = 6) and grade II-IV (D-F, n = 8) versus time-matched control subjects (n = 22 and n = 24, respectively) are shown. Mean quantity (± SD) of lymphocytes (A and D), CD3+CD4+/CD3+CD4− T cells (B and E), and IL-17/IFN-γ–producing T helper cells (C and F) are indicated in GPt/L, MPt/L, or KPt/L. n.s., not significant. Biology of Blood and Marrow Transplantation 2013 19, 357-365DOI: (10.1016/j.bbmt.2012.11.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Modulation of lymphocyte, CD3+CD4+/CD3+CD4− T cells, and Th1, Th17, and Th1/17 cell counts by CMV reactivation (A-C) and early bacterial infection (D-F). Data of patients with CMV reactivation (A-C, n = 7) and early bacterial infection (D-F, n = 15) versus time-matched control subjects (n = 21 and n = 20, respectively) are shown. Mean quantity (± SD) of lymphocytes (A and D), CD3+CD4+/CD3+CD4− T cells (B and E), and IL-17/IFN-γ–producing T helper cells (C and F) are indicated in GPt/L, MPt/L, or KPt/L. *P < .05, **P < .01, ***P < .001, n.s., not significant. Biology of Blood and Marrow Transplantation 2013 19, 357-365DOI: (10.1016/j.bbmt.2012.11.018) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions